Wallace Weitz

Wallace Weitz

Last Update: 02-14-2017

Number of Stocks: 84
Number of New Stocks: 21

Total Value: $2,469 Mil
Q/Q Turnover: 7%

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

Wallace Weitz Watch

  • 8 Rising Stocks That Are Still Undervalued

    According to the GuruFocus All-in-One Screener, several gurus are focusing on stocks whose Peter Lynch fair values are far above the current price. The following stocks are trading with wide margins of safety and have positive performances over the past 12 months.


    GigaMedia Ltd. (GIGM) is trading around $3.08 per share. The Peter Lynch value gives the stock a fair price of $20.75 so the stock is undervalued with a margin of safety of 89%. Twelve weeks ago the stock started its positive upward trend; it now registers a positive performance of 21.79%.

      


  • Weitz Funds Comments on EOG Resources

    EOG Resources (NYSE:EOG) is an independent producer of crude oil and natural gas, with operations focused in the major producing basins in the U.S. (namely the Bakken, Eagle Ford and Permian). EOG boasts some of the highest quality hydrocarbon producing assets in North America as well as a culture firmly centered on return on invested capital.


    Its unique ability to continually reduce both costs and the capital employed in the production process places the company among the most efficient producers of oil and gas in the world. We purchased shares in EOG in the fall of 2015 amid significant downward pressure on oil prices. Management’s ability to unlock an inventory of over 4,000 high-return wells (assuming $40 oil prices) within its existing acreage through continued process improvements, in addition to its successful acquisition of Yates Petroleum, exceeded our expectations and rightly excited investors. With oil prices rebounding and EOG’s discount to value narrowing, we sold our shares during the fourth quarter at a nice gain. We would gladly own EOG again at the right price.

      


  • Weitz Funds Comments on Express Scripts

    Express Scripts (NASDAQ:ESRX) is the largest stand-alone pharmacy benefits manager (PBM) in the U.S., helping health benefit providers improve access to (and the affordability of) prescription drugs. The ongoing impasse with its largest customer (Anthem), an evolving competitive landscape, and public finger pointing between so-called middlemen and drug manufacturers as to the source of persistent drug inflation led us to (once again) test the assumptions underlying our notion of Express’s business value. Our additional diligence suggested an increased probability of Anthem not renewing with Express Scripts in 2019. In addition, the likelihood that competitive or industry pressures offset a portion (potentially even all) of other future profit-per-script drivers seem to have increased, particularly for Express. This combination made the risk-reward trade-off less compelling, and we elected to close our position in Express across the funds following the post-election rally in November.


    • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.
    •   


  • Weitz Funds Comments on CVS Health

    CVS Health (NYSE:CVS) operates a nationwide network of nearly 10,000 retail pharmacies, the nation’s second largest pharmacy benefits manager (PBM) in Caremark, and sizeable specialty and long-term care pharmacy platforms. This is the fund’s second go around with CVS, having last owned it back in 2013. CVS’ stock has been under pressure for most of the last 18 months after peaking during the summer of 2015. After nearly five years of consistent market share gains, the Caremark PBM suffered several client losses over the course of 2016. In addition, CVS also announced that its retail pharmacies would no longer be part of several important networks in 2017. These lost volumes will likely result in no earnings per share growth this year. These near-term negatives drove the stock down to a price that we found attractive. While management will need to navigate several risks over the course of the next couple of years, we believe CVS’ stock price provides an attractive valuation in the mid-$70s.


    • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.
    •   


  • Weitz Funds Comments on Amazon.com

    Amazon.com (NASDAQ:AMZN) is an e-commerce and cloud computing company. We believe that Amazon has built a global competitive advantage that will allow it to obtain a material share of the worldwide retail (not just e-commerce) market over a long period of organic growth. Amazon’s strong, customer-obsessed culture is unique among technology and retail firms, which has provided several new long-term investment opportunities. In addition to the retail business, the company’s Amazon Web Service (AWS) business has built significant share and scale within the infrastructure as a service market. AWS business is highly profitable and participates in a large and growing market.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Funds Comments on Thermo Fisher Scientific

    Thermo Fisher Scientific (NYSE:TMO) provides analytical instruments, equipment, reagents and consumables, as well as software and services for research, analysis, discovery and diagnostics across most of the globe. Thermo is well-diversified by both product and end market, boasting strong defensible market positions and reputable brands. Roughly three quarters of the company’s revenues are recurring in nature (consumables and services), consistent with our preference for subscription-like cash flow streams. Its portfolio of businesses is characterized by stable pricing, relatively acyclical organic growth and consistent excess cash generation. We believe the life sciences tools and diagnostics industry is a “good neighborhood,” characterized by relatively high entry barriers, high customer switching costs and rational competitive behavior. Currency headwinds and investor rotation toward more cyclically- exposed areas of the industrial and healthcare sectors left Thermo’s stock largely unchanged the past 18 months while our estimate of business value grew nicely. We took advantage, initiating a position at, what we believe is, an attractive valuation.


    • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.
    •   


  • Weitz Funds Comments on Visa

    Visa (NYSE:V) is the world’s largest electronic payment network. The company recently closed on its acquisition of Visa Europe, allowing it to provide a fully integrated network to clients, which should result in increased market share and lower costs. We believe Visa will compound nicely as worldwide payment volumes grow, developing countries switch from cash to cards and the company uses its technology and network to participate in all forms of electronic payments.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Funds Comments on McKesson

    McKesson (NYSE:MCK) distributes drugs, equipment and health and beauty care products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Shares of McKesson declined in October as the company experienced unexpected competitive losses from its core independent pharmacy customer base. The source (price competition) and magnitude of these developments led to a downward revision in McKesson’s earnings power and undermined one of the pillars of our investment thesis – that drug wholesalers operate within a competitive, but otherwise rational, oligopoly. Our estimate of McKesson’s business value declined, and we elected to close our small position at a modest loss.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Funds Comments on Allergan

    Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter pharmaceutical products. Following a brief post-election rally, the majority of the biopharmaceutical sector retreated to prior price levels as capital continued to flow out of healthcare and into industries seen as potential beneficiaries of policy shifts under the new administration. After downwardly revising future growth expectations in August and again in early November, Allergan has become a “show me” story. Patent challenges for Restasis (dry eye treatment) and Namenda XR (alzheimer’s drug) may continue to weigh on the stock in the near term, though each contributes only a small percentage of our estimate of the company’s overall intrinsic value. Over the next 3-5 years, we believe the company will have healthy mid-single digit (or better) operating profit growth. 80% of the company’s recently announced $10 billion accelerated share repurchase program is complete at an average price below $200 per share. We believe this will prove to be a prudent use of excess cash in the long run. Future capital deployment and late-stage pipeline success remain potential positives over the next 12 -24 months. We continue to believe Allergan shares present compelling value at current prices.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Funds Comments on Twenty-First Century Fox

    Twenty-First Century Fox (NASDAQ:FOXA) is a diversified media and entertainment company. Sentiment has been generally positive as investors were reminded of the power of live, must-have content. The month of October featured two of the most widely watched presidential debates in history and five of seven World Series games that delivered the best ratings in over a decade. Investors have been further comforted by Fox’s presence in all of the major “skinny bundles” announcements and new online Pay-TV distribution packages. Finally, in December, Fox announced an offer to acquire the remaining shares of Sky plc. The announced offer for Europe’s premier satellite Pay-TV and content (sports and entertainment) company resolves a long-standing question of how to resolve Fox’s 39% minority stake in the entity. We continue to be encouraged by the prospect for continued improvement at Fox’s domestic channels and continued growth opportunities internationally.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Funds Comments on Wells Fargo

    Wells Fargo (NYSE:WFC) is a diversified financial services company. Shares rose materially during the quarter largely due to three tailwinds. First, the U.S. election results provided a boost to all bank stocks on expectations that industry regulatory burdens may ease. Second, higher interest rates and a steeper yield curve raised prospects for net interest margin (NIM) expansion. Third, the company took additional steps to address the “bogus account” scandal, including high-level management changes. The company’s very low-cost deposit base, ubiquitous distribution, ample capital and diverse business lines further our continued confidence. Wells Fargo’s stock trades at less than 14x expected earnings and a modest discount to our value estimate.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Funds Comments on Endo International

    Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Funds Comments on Liberty Global

    Liberty Global (NASDAQ:LBTYA) is the largest international cable company, with operations across Europe providing video, broadband Internet, fixed-line telephone and mobile services to its customers. Throughout 2016, Liberty Global suffered as the translational impact of a stronger U.S. dollar muted its reported financial results. Liberty’s revenues and expenses are generally denominated in the local currencies of its European operations, but its dollar denominated stock can create mismatches from time to time. Shares weakened, particularly in the wake of this summer’s “Brexit” vote, as the UK is the company’s largest market. Shares have recouped some of these losses as the market has further digested the Brexit event. Meanwhile, the results from the company’s new build program in the UK appear to be solid, and the pace of adding newly connected homes should accelerate into 2017. We remain confident in management’s plans to drive cost efficiencies and their new build investment strategy to provide future growth.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Funds Comments on Range Resources

    Range Resources (NYSE:RRC) is an independent producer of natural gas and natural gas liquids (NGLs) based in Fort Worth, Texas, with operations in the Marcellus shale and emerging Terryville field. Range’s stock cooled some during the second half of the year following a strong first half rebound from its January lows. A more normal start to winter and low overall drilling activity has led to much needed draws on natural gas storage, with present levels now below the 5 -year average for the first time in almost two years. Near-term gas prices have rebounded accordingly, but uncertainty around mid-cycle gas prices continues as oil drilling activity resumes (increasing competition from “associated” gas production) and Appalachian pipeline capacity increases significantly later this year. Range should be a direct beneficiary of the latter, supporting the company’s 20% production growth aspiration in 2018. While gas prices will likely always be volatile, we believe that at $2.75 or better, Range shares offer significant value.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Funds Comments on Berkshire Hathaway

    Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) is a conglomerate holding company owning subsidiaries engaged in a number of business activities. Shares benefited from optimism that a combination of higher interest rates, lower taxes and increased domestic activity would increase earnings at Berkshire’s insurance and industrial businesses.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Funds Comments on Liberty Broadband

    Liberty Broadband (NASDAQ:LBRDA) is a holding company for Liberty’s ownership stake of Charter Communications. Shares of Charter, and cable companies broadly, have performed well in the wake of the U.S. election. Although much remains to be seen, investors generally believe that regulatory pressures will ease as a result of a presumably more “industry friendly” Federal Communications Commission (FCC) as well as a Justice Department that may look more favorably on further industry consolidation. Investors are also hopeful that either the FCC or a Republican-controlled Congress will revisit actions of the previous FCC, including the more controversial actions taken as part of its “Net Neutrality” packages. We have invested in Liberty Broadband because we like the operating strategy at Charter, and while regulatory relief would certainly be a benefit, it’s not an explicit part of our investment thesis. Liberty Broadband shares trade at a discount to their underlying Charter investment due to the added complexity of Liberty’s involvement. We are confident Liberty’s management will ultimately collapse this discount, thereby making Liberty Broadband a cheaper opportunity to invest in Charter’s future.


    From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.

      


  • Weitz Investment Management's Value Fund 4th Quarter Commentary

    Investment Style: Large-Cap Value


    The Value Fund’s Institutional Class returned +1.27% in the fourth calendar quarter, compared to +3.82% for the S&P 500 and +3.83% for the Russell 1000. For the calendar year, the Value Fund’s Institutional Class returned +3.13%, compared to +11.96% for the S&P 500 and +12.05% for the Russell 1000.

      


  • Wally Weitz's Value Matters for 4th Quarter

    Dear Fellow Investor:


    Last year saw plenty of action in the stock, bond and currency markets, but our guess is that 2016 will be remembered for its presidential election. It is hard to be politically neutral in discussing the election. As individuals and citizens, we have strong opinions about the new administration. We will spare you those thoughts, though, and focus on what we see as implications for investors.

      


  • Learning From the Biggest Mistakes of Institutional Investors

    Every investor makes mistakes. If someone tells you they do not, they are either lying or too inexperienced.


    Mistakes are a natural part of investing. Even Warren Buffett (Trades, Portfolio), who is widely considered the world’s most knowledgeable investor, has made some serious errors in his career. In fact, Buffett has said acquiring Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) was his biggest mistake, and look how that turned out.

      


  • Express Scripts to Include Harvoni in Hepatitis Cure Value Program

    As announced by Express Scripts (NASDAQ:ESRX) through PR Newswire Dec. 12, the program that targets the treatment of patients affected with the hepatitis C virus, called “Hepatitis Cure Value Program,” will be upgraded with another product in January.


    Gilead Sciences' (NASDAQ:GILD) Harvoni will be added to AbbVie's (NYSE:ABBV) Viekira Pak for the treatment of HCV patients.

      


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)